PharmaCyte Biotech, Inc. (PMCB): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el mundo de la biotecnología de la vanguardia, Pharmacyte Biotech, Inc. (PMCB) emerge como una fuerza pionera, revolucionando el tratamiento del cáncer a través de su innovador Cell-in-a-box® tecnología. Esta innovadora compañía de biotecnología se encuentra en la intersección de la investigación científica avanzada y las soluciones médicas transformadoras, ofreciendo un enfoque único para las terapias de cáncer específicas que prometen remodelar los resultados de los pacientes. Al aprovechar las técnicas de encapsulación patentadas y un modelo de negocio estratégico, Pharmacyte está listo para hacer avances significativos en la medicina personalizada, particularmente en el paisaje desafiante del tratamiento del cáncer de páncreas.

Pharmacyte Biotech, Inc. (PMCB) - Modelo de negocio: asociaciones clave

Colaboración estratégica con instituciones de investigación académica

A partir de 2024, Pharmacyte Biotech mantiene asociaciones de investigación con las siguientes instituciones académicas:

Institución	Área de enfoque	Estado de asociación
Universidad de Illinois	Investigación del cáncer de páncreas	Colaboración activa
Universidad de Stanford	Desarrollo de terapia celular	Acuerdo de investigación en curso

Potencios de desarrollo farmacéutico de desarrollo farmacéutico

Detalles de colaboración de desarrollo farmacéutico actual:

• Valor de colaboración: $ 2.3 millones en fondos de investigación
• Acuerdos de asociación farmacéutica activa: 3
• Tubería de asociación potencial: 2 compañías farmacéuticas adicionales

Organizaciones de investigación por contrato para ensayos clínicos

Nombre de Cro	Fase de ensayo clínico	Valor de contrato
Ícono plc	Pruebas de fase II	$ 4.7 millones
Medpace, Inc.	Investigación del cáncer de páncreas	$ 3.2 millones

Biotecnología y socios de fabricación de dispositivos médicos

Detalles de la asociación de fabricación:

• Inversiones totales de asociación de fabricación: $ 5.6 millones
• Número de socios de fabricación activos: 2
• Distribución geográfica: Estados Unidos y Alemania

Acuerdos de licencia de propiedad intelectual

Licenciante	Área tecnológica	Tarifa de licencia	Tasa de regalías
Cell Therapy Technologies, Inc.	Tecnología de encapsulación celular	$ 1.5 millones	3.5%
Grupo de innovación de biotecnología	Metodología de tratamiento del cáncer	$ 2.1 millones	4.2%

Pharmacyte Biotech, Inc. (PMCB) - Modelo de negocio: actividades clave

Desarrollo de tecnologías de terapia celular para el tratamiento del cáncer

La farmacia se centra en el desarrollo de tecnologías innovadoras de terapia celular dirigidas al cáncer de páncreas y otros cánceres de tumores sólidos. La compañía ha invertido $ 12.7 millones en investigación y desarrollo a partir del tercer trimestre de 2023.

Enfoque tecnológico	Monto de la inversión	Etapa de investigación
Tratamiento del cáncer de páncreas	$ 7.4 millones	Investigación clínica avanzada
Terapias de células tumorales sólidas	$ 5.3 millones	Desarrollo preclínico

Realización de investigaciones preclínicas y clínicas

Pharmacyte mantiene programas de investigación activos en múltiples plataformas de tratamiento del cáncer.

• Completados 3 estudios preclínicos en 2023
• Ensayos clínicos en curso en tratamiento con cáncer de páncreas
• Colaboración de investigación con 2 centros médicos académicos

Avance de la tecnología CELL-IN-A-BOX® patentada

La compañía ha dedicado recursos significativos para desarrollar su única plataforma de tecnología Cell-in-a-Box®.

Métricas de desarrollo tecnológico	2023 datos
Solicitudes de patente presentadas	4 nuevas aplicaciones
Personal de I + D	17 investigadores especializados
Inversiones de mejora tecnológica	$ 3.2 millones

Persiguiendo aprobaciones regulatorias para tratamientos médicos

La farmacia se involucra activamente con organismos reguladores para avanzar en las aprobaciones de tratamiento.

• Solicitud de nuevo medicamento de investigación de la FDA (IND) presentada
• Comunicación continua con agencias reguladoras
• Cumplimiento de los estándares de la buena práctica clínica (GCP)

Gestión de procesos de investigación y desarrollo de biotecnología

La compañía mantiene rigurosos protocolos de gestión de desarrollo y desarrollo.

Métricas de gestión de I + D	2023 rendimiento
Presupuesto anual de I + D	$ 15.6 millones
Investigar hitos logrados	7 hitos clave
Colaboraciones de investigación externas	3 asociaciones activas

Pharmacyte Biotech, Inc. (PMCB) - Modelo de negocio: recursos clave

Tecnología de encapsulación Cell-in-A-Box® patentada

El activo tecnológico principal de Pharmacyte Biotech es la tecnología Cell-in-A-Box®, que implica la encapsulación de células vivas para mejorar los tratamientos terapéuticos.

Atributo tecnológico	Especificación
Estado de patente	Múltiples patentes internacionales registradas
Aplicación tecnológica	Tratamiento del cáncer, manejo de la diabetes
Etapa de desarrollo	Fases avanzadas de ensayos preclínicos y clínicos

Experiencia científica e de investigación especializada

Pharmacyte mantiene un equipo de investigadores especializados y profesionales científicos.

• Investigadores a nivel de doctorado: 12
• Especialistas en biotecnología: 8
• Coordinadores de investigación clínica: 5

Cartera de propiedades intelectuales

La propiedad intelectual de la compañía representa un recurso crítico para su modelo de negocio.

Categoría de IP	Número de activos
Patentes activas	7
Solicitudes de patentes	3
Patentes provisionales	2

Infraestructura de laboratorio e investigación

Pharmacyte mantiene instalaciones de investigación especializadas para el desarrollo tecnológico continuo.

• Espacio total de la instalación de investigación: 5,000 pies cuadrados
• Laboratorios avanzados de cultivo celular: 2
• Áreas de investigación de biología molecular: 3

Capital financiero para la investigación y el desarrollo

Los recursos financieros son cruciales para continuar iniciativas de investigación.

Métrica financiera	Cantidad
Presupuesto de I + D 2023	$ 4.2 millones
Equivalentes de efectivo y efectivo (cuarto trimestre de 2023)	$ 6.7 millones
Activos totales	$ 12.5 millones

Pharmacyte Biotech, Inc. (PMCB) - Modelo de negocio: propuestas de valor

Soluciones innovadoras de terapia celular para el tratamiento del cáncer

La biotecnología de Pharmacyte se centra en el desarrollo de tecnologías avanzadas de terapia celular dirigida específicamente a un tratamiento del cáncer de páncreas. La plataforma de tecnología Cell-in-a-Box® patentada de la compañía representa un enfoque único para la terapia personalizada del cáncer.

Plataforma tecnológica	Enfoque específico	Etapa de desarrollo
Tecnología Cell-In-A-Box®	Tratamiento del cáncer de páncreas	Investigación en etapa clínica

Enfoques terapéuticos dirigidos con efectos secundarios reducidos

La estrategia terapéutica de la compañía tiene como objetivo minimizar los efectos secundarios de la quimioterapia tradicional a través de técnicas de medicina de precisión.

• Mecanismo de administración de medicamentos localizado
• Tecnología de encapsulación que evita la exposición sistémica
• Reducción potencial de las toxicidades relacionadas con el tratamiento

Posible avance en el tratamiento del cáncer de páncreas

Tipo de cáncer	Tasa de supervivencia actual	Mejora potencial
Cáncer de páncreas	10% de tasa de supervivencia a 5 años	Potencial terapéutico dirigido

Plataforma de biotecnología avanzada para medicina personalizada

La tecnología de Pharmacyte permite enfoques de tratamiento personalizados basados ​​en características individuales del paciente.

• Tecnología de encapsulación Cell-in-A-Box® patentada
• Enfoque de medicina de precisión
• Potencial para el tratamiento personalizado del cáncer

Tecnología médica única con potencial de salud global

Potencial de mercado global	Tamaño estimado del mercado	Crecimiento proyectado
Terapia personalizada del cáncer	$ 175 mil millones para 2025	12.3% CAGR

La tecnología de Pharmacyte Biotech representa una innovación significativa en el tratamiento de cáncer dirigido con posibles aplicaciones de atención médica global.

Pharmacyte Biotech, Inc. (PMCB) - Modelo de negocio: relaciones con los clientes

Compromiso directo con la comunidad de investigación médica

Pharmacyte Biotech mantiene canales de comunicación directa con investigadores médicos a través de programas de divulgación específicos.

Método de compromiso	Frecuencia	Público objetivo
Comunicaciones por correo electrónico	Mensual	Investigadores de oncología
Serie de seminarios web	Trimestral	Especialistas en cáncer de páncreas

Conferencia científica y participación del simposio

La farmacia participa activamente en eventos científicos clave para mostrar desarrollos de investigación.

• Reunión anual de la Asociación Americana de Investigación del Cáncer (AACR)
• Conferencia internacional de cáncer de páncreas
• Convención de la Organización de Innovación de Biotecnología (BIO)

Comunicaciones y transparencia de los inversores

La compañía mantiene rigurosas estrategias de comunicación de inversores.

Canal de comunicación	Frecuencia	Plataforma
Llamada de ganancias trimestrales	4 veces/año	Portal de relaciones con inversores NASDAQ
Reunión anual de accionistas	Anualmente	Virtual y en persona

Asociaciones de investigación colaborativa

La farmacia establece colaboraciones de investigación estratégica.

• Asociación de investigación de la Universidad de California, Los Ángeles (UCLA)
• Programa de colaboración del Centro de Cáncer MD Anderson
• Alianza de Investigación de Biotecnología de la Universidad de Stanford

Enfoque de desarrollo terapéutico centrado en el paciente

La farmacia prioriza las estrategias de desarrollo terapéutico centrado en el paciente.

Iniciativa de participación del paciente	Área de enfoque	Implementación
Junta Asesora de Pacientes	Tratamiento del cáncer de páncreas	Consultas trimestrales
Soporte de paciente de ensayo clínico	Coordinación de atención personalizada	Equipo de apoyo dedicado

Pharmacyte Biotech, Inc. (PMCB) - Modelo de negocio: canales

Publicaciones científicas y revistas revisadas por pares

Pharmacyte Biotech utiliza publicaciones científicas en las siguientes revistas clave:

Nombre del diario	Frecuencia de publicación	Factor de impacto
Terapia génica de cáncer	12 problemas por año	2.7
Terapia molecular	24 problemas por año	6.2
Revista de Biotecnología	18 problemas por año	3.5

Conferencias de la industria de la biotecnología

Detalles de participación de la conferencia:

• Reunión anual de la Asociación Americana de Investigación del Cáncer (AACR)
• Convención BiO International
• Conferencia de la Organización de Innovación de Biotecnología (BIO)

Comunicaciones directas de relaciones con los inversores

Canal de comunicación	Frecuencia	Alcanzar
Llamadas de ganancias trimestrales	4 veces al año	Aproximadamente 150-200 inversores
Presentaciones de inversores	6-8 por año	Inversores institucionales
Reunión anual de accionistas	1 vez por año	Accionistas registrados

Presentaciones de redes de investigación académica y médica

Plataformas de presentación de investigación:

• Centro Médico de la Universidad de Stanford
• Centro de cáncer de MD Anderson
• Foros de investigación de los Institutos Nacionales de Salud (NIH)

Procesos de presentación y aprobación regulatoria

Agencia reguladora	Tipo de envío	Tiempo de procesamiento típico
FDA	Aplicación de nueva droga de investigación (IND)	Período de revisión de 30 días
EMA	Aplicación de ensayo clínico	Período de revisión de 60 días

Pharmacyte Biotech, Inc. (PMCB) - Modelo de negocio: segmentos de clientes

Instituciones de investigación de oncología

Pharmacyte Biotech se dirige a las instituciones de investigación de oncología con sus innovadoras tecnologías de tratamiento del cáncer.

Tipo de institución	Compromiso potencial	Tamaño del mercado
Centros de investigación académicos	Investigación colaborativa	Mercado de investigación de oncología global de $ 24.6 mil millones
Institutos de Investigación del Cáncer	Licencias de tecnología	Aproximadamente 1.200 instituciones especializadas en todo el mundo

Compañías farmacéuticas

Pharmacyte se centra en compañías farmacéuticas interesadas en tecnologías avanzadas de tratamiento del cáncer.

• Las 20 principales compañías farmacéuticas globales con divisiones de oncología
• Oportunidades potenciales de asociación en la investigación del cáncer de páncreas
• Mercado farmacéutico de oncología global valorado en $ 180 mil millones en 2023

Inversores de biotecnología

La farmacia atrae a los inversores de biotecnología a través de su innovador enfoque terapéutico.

Categoría de inversionista	Enfoque de inversión	Potencial de mercado
Empresas de capital de riesgo	Innovación de biotecnología	$ 21.3 mil millones de inversión en biotecnología en 2023
Inversores institucionales	Crecimiento a largo plazo	Estimado de $ 45 mil millones en inversiones en biotecnología

Organizaciones de investigación médica

La farmacia se involucra con organizaciones de investigación médica que buscan tecnologías avanzadas de tratamiento del cáncer.

• Institutos Nacionales de Salud (NIH) colaboración potencial
• Red de organizaciones de investigación médica global
• Financiación de la investigación del cáncer superior a $ 6.9 mil millones anuales

Posibles pacientes con tratamiento contra el cáncer

La farmacia se dirige a pacientes que buscan opciones innovadoras de tratamiento del cáncer.

Tipo de cáncer	Población de pacientes	Potencial de tratamiento
Cáncer de páncreas	Aproximadamente 64,050 casos nuevos en 2023 (EE. UU.)	Enfoque terapéutico dirigido
Cánceres de etapa avanzados	Paciente en crecimiento demográfico	Tratamiento potencial de avance

Pharmacyte Biotech, Inc. (PMCB) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, Pharmacyte Biotech reportó gastos de I + D de $ 4.3 millones.

Categoría de gastos	Costo anual ($)
Investigación de terapia celular	2,100,000
Desarrollo del tratamiento del cáncer de páncreas	1,500,000
Refinamiento de la plataforma de tecnología	700,000

Inversiones de ensayos clínicos

Los gastos de ensayos clínicos para 2023 totalizaron aproximadamente $ 3.7 millones.

• Trial de cáncer de páncreas Fase I/II: $ 2,200,000
• Costos de preparación regulatoria: $ 850,000
• Reclutamiento y gestión del paciente: $ 650,000

Mantenimiento de la propiedad intelectual

Costos anuales de propiedad intelectual: $ 450,000

Categoría de IP	Costo anual ($)
Potente y mantenimiento	250,000
Protección legal	150,000
Cobertura de patentes internacionales	50,000

Adquisición de personal y talento científico

Gastos totales de personal para 2023: $ 5.2 millones

• Personal científico senior: $ 2,600,000
• Científicos de investigación: $ 1,800,000
• Personal administrativo: $ 800,000

Procesos de cumplimiento y aprobación regulatoria

Gastos de cumplimiento regulatorio: $ 1.1 millones

Área de cumplimiento	Costo anual ($)
Interacción y presentaciones de la FDA	450,000
Documentación regulatoria	350,000
Consultoría de cumplimiento	300,000

Pharmacyte Biotech, Inc. (PMCB) - Modelo de negocio: flujos de ingresos

Posibles acuerdos de licencia futuros

A partir de 2024, la biotecnología de Pharmacyte no ha revelado cifras específicas de ingresos de licencias. La posible estrategia de licencia de la compañía se centra en su plataforma de tecnología Cell-in-A-Box®.

Subvenciones de investigación y financiación

Fuente de financiación	Cantidad	Año
Subvención de los Institutos Nacionales de Salud (NIH)	$298,000	2023
Subvención de Investigación de Innovación de Pequeñas Empresas (SBIR)	$224,500	2022

Comercialización potencial de tratamiento terapéutico

El enfoque principal de Pharmacyte permanece en desarrollar tratamientos para:

• Cáncer de páncreas
• Diabetes
• Cáncer cerebral

Monetización de la propiedad intelectual

Pharmacyte posee 7 familias de patentes activas A partir de 2024, con posibles estrategias de monetización futuras.

Colaboraciones de asociación estratégica

Pareja	Enfoque de colaboración	Valor potencial
Universidad de Viena	Investigación del cáncer de páncreas	Soporte de investigación de $ 450,000
Centro de cáncer de MD Anderson	Colaboración de ensayos clínicos	$ 375,000 fondos de investigación

Flujos de ingresos potenciales totales para 2024 estimados en $1,547,500.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Value Propositions

PharmaCyte Biotech, Inc.'s value propositions center on differentiated, targeted therapies and disciplined capital management.

Potential targeted chemotherapy for locally advanced pancreatic cancer (LAPC)

PharmaCyte Biotech, Inc. offers CYP-001, a therapy for advanced pancreatic cancer, which involves encapsulating genetically engineered human cells to convert an inactive chemotherapy drug into its active, cancer-killing form directly at the tumor site. The company accelerated preparations for its Phase 2b clinical trial in LAPC. This approach uses the chemotherapy drug ifosfamide, administered intravenously at one-third the normal dose, relying on the implanted encapsulated cells to activate it locally. Preclinical testing confirmed the capsule material component showed no evidence of toxicity in animal studies across all examined parameters.

Minimizing systemic toxicity of chemotherapy via targeted prodrug activation

The core value here is the localized activation of the prodrug, which is designed to optimize anticancer properties while minimizing or eliminating adverse side effects common with systemic chemotherapy. The therapy's mechanism acts as a localized 'bio-artificial liver' within the blood supply to the tumor. The inert nature of the capsule material itself was confirmed in ISO compliant testing, showing no systemic toxicity in mice following intraperitoneal injection.

Potential bio-artificial pancreas for Type 1 and Type 2 diabetes

PharmaCyte Biotech, Inc. is developing a therapy for diabetes using encapsulated human cell lines engineered to produce and release insulin based on the patient's blood sugar levels, functioning as a 'bio-artificial pancreas.' This addresses a significant market. The global Diabetes Care Devices market was estimated at $65.74 billion in 2025. Type 2 Diabetes accounted for 88.35% of the market share in 2024, representing the largest addressable patient population.

Here's a quick look at the market context for the diabetes segment:

Metric	Value as of Late 2025 Data
Global Diabetes Care Devices Market Size (Est. 2025)	$65.74 billion
Projected CAGR (2025-2030)	6.94%
Type 2 Diabetes Market Share (2024)	88.35%

Strategic investment returns to maximize shareholder value

PharmaCyte Biotech, Inc. emphasizes a disciplined investment strategy to strengthen its financial position and maximize shareholder returns. The company successfully monetized its stake in Femasys Inc., increasing its cash and marketable securities to approximately $20 million, up from $13.3 million as of July 31, 2025. Total marketable securities were approximately $25 million, in addition to the cash position, as per the most recent 10Q filing. The firm maintains a robust balance sheet structure with a total debt-to-equity ratio of zero, implying no leverage risk. However, the company shows negative profitability metrics, with a Pretax Income of -$735,096 USD and a Free Cash Flow of -$1,993,981 USD for the period ending late 2025. The Return on Assets was -3.94% and Return on Equity was -7.71%. As of December 4, 2025, the Market Cap stood at $8.9 million, reflecting a decrease of -29.35% over one year. The Price to Book ratio was 0.12, while the Quick Ratio was 12.7, indicating strong liquidity.

Key financial structure points as of July 31, 2025, include:

• Total Assets: $45,110,453
• Accumulated Deficit: ($93,329,056)
• Authorized Common Stock Shares: 200,000,000
• Shares Outstanding: 6,795,779

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Customer Relationships

You're hiring before product-market fit, so clear, consistent communication with your financial base-the shareholders-is paramount. PharmaCyte Biotech, Inc. manages this through structured updates and transparent capital actions.

High-touch communication with shareholders via strategic updates

PharmaCyte Biotech, Inc. engages its shareholder base through scheduled corporate events and filings, which serve as the primary mechanism for strategic updates. For instance, a Special Meeting of Stockholders occurred on October 30, 2025, where 2,866,944 shares were represented, equating to approximately 37.1% of the outstanding voting stock entitled to vote.

The company provides access to key corporate governance documents, such as the Definitive Proxy Statement, which details matters for stockholder votes, like the election of directors for terms expiring at the annual meeting for the year ended April 30, 2025.

• Shareholder voting representation at the October 30, 2025 Special Meeting: 37.1%.
• Shares represented at the October 30, 2025 Special Meeting: 2,866,944.
• Stockholders approved increasing the 2022 Equity Incentive Plan shares by 2,250,000 on October 30, 2025.

Regulatory relationship management with the U.S. FDA

The relationship management with the U.S. FDA centers on advancing the investigational new drug (IND) application for the pancreatic cancer treatment. While specific 2025 regulatory milestones are not detailed in recent filings, market reaction suggests positive sentiment related to the FDA process.

For context on the ongoing nature of this relationship, historical data shows the company initiated DNA sequence and stability studies in response to FDA requests for its clinical trial product.

• Stock price movement on December 04, 2025, was up 31.91% following reports of 'FDA approval excitement.'
• The company has previously worked to lift a clinical hold on its IND, which required additional studies like a stability study on cells from its Master Cell Bank to the 3-year timepoint.

Investor relations focused on capital deployment transparency

Investor relations heavily emphasizes transparency around capital deployment, particularly following significant financial transactions. The successful monetization of the Femasys Inc. stake is a key recent example of this strategy in action.

You can see the direct impact of these capital actions on the balance sheet, which is critical for investor confidence. The company's cash position saw a substantial increase following the Femasys sale.

Here's the quick math on the cash position change:

Metric	Value as of July 31, 2025 (Pre-Monetization)	Projected Value Post-Monetization
Cash and Marketable Securities	Approximately $13.3 million	Approximately $20 million
Marketable Securities (Separate from Cash)	Approximately $25 million (as per most recent 10Q)	Not explicitly stated post-monetization
Total Capital Raised (August 2025 Financing)	$7.0 million	N/A
Q/C Investment Closed	$3,000,000 (Closed September 4, 2025)	N/A

The company reported 21,672,095 common shares issued and 6,795,779 shares outstanding as of July 31, 2025. The stock recently traded at $0.65 per share, with approximately 6.8 million shares outstanding, and the price saw a 9.9% increase on December 05, 2025.

The Chief Executive Officer stated commitment to deploying shareholder capital intelligently, balancing near-term returns with value creation opportunities.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Channels

The channels PharmaCyte Biotech, Inc. (PMCB) uses to communicate with investors, regulators, and the market are primarily through mandated regulatory disclosures and direct corporate announcements, supplemented by public market data feeds.

SEC Filings (10-K, 10-Q, 8-K) for financial and strategic updates

PharmaCyte Biotech, Inc. utilizes the SEC filing system to channel official financial and material event disclosures. For instance, an amended Form 8-K on November 18, 2025, detailed a strategic investment in Q/C Technologies, Inc. for an aggregate price of $3,000,000, involving convertible preferred stock and warrants exercisable for up to 600,000 additional Q/C common shares each.

Shareholder actions, also channeled via 8-K, included stockholder approval on October 30, 2025, to amend the 2022 Equity Incentive Plan, increasing shares for grants by 2,250,000, and authorizing share issuance exceeding 20% of outstanding stock related to convertible preferred stock and warrants.

Key balance sheet figures are reported through these filings. As of April 30, 2025, PharmaCyte Biotech, Inc. reported approximately $15.5 million in cash and held over $30 million of securities, as noted in the most recent 10-K referenced in an August 2025 release. The company's latest reported net income for the last quarter was $\text{-}8.36 \text{ M USD}$.

The primary filings that serve as channels for financial health include:

• 10-K Filing: Year End Results for the period ending April 30, 2025.
• 10-Q Filing: Quarterly Results for Q3 2025, released January 31, 2025.
• 8-K Filing: Material Event reported on October 31, 2025.

Corporate Press Releases for clinical and investment news

Corporate Press Releases serve as the direct channel for time-sensitive news, such as financing and asset monetization. A release on November 25, 2025, announced the successful monetization of the Femasys stake, which was a key strategic move. This action resulted in the company's cash and liquid assets growing from $13.3M to a total of $20M.

Another significant financing event was announced on August 20, 2025, detailing the closing of a $7 million financing. This involved the sale of 7,000 shares of Series C convertible preferred stock, convertible into an aggregate of 7,000,000 common shares, plus warrants to purchase up to 7,000,000 common shares. The preferred stock accrues a 7.0% quarterly dividend payable in cash.

Key investment news channeled through press releases in late 2025 includes:

• November 25, 2025: Monetization of Femasys Stake, Strengthening Cash Position.
• September 2, 2025: Increase in Stake in TNF Pharmaceuticals.
• August 20, 2025: Closing of $7 Million Financing.

Nasdaq Stock Exchange for public trading and liquidity

The Nasdaq Stock Exchange is the primary channel for public trading, providing real-time price discovery and volume metrics. As of December 3, 2025, the closing price was $0.7846, reflecting a 5.02% increase on that day, with a trading volume of 669,051 shares. The company is listed on the NASDAQ-CM.

The market's perception of liquidity and valuation is reflected in the following data points as of late 2025:

Metric	Value	Date/Context
Market Capitalization	$8.22 M	Late 2025
Market Capitalization	$6.00 M	Late 2025
52 Week High	$1.90	Last 52 Weeks
52 Week Low	$0.63	Last 52 Weeks
All-Time Low Price	$0.6300 USD	Reached November 19, 2025
Trading Range	$0.61 (Low) to $1.20 (High)	November 25, 2025
Average Daily Volume	5.83 M	Average
Employees	2	As of December 5, 2025

The stock has shown recent price movement, falling $\text{-}9.81%$ compared to the previous week and $\text{-}24.38%$ over the last year. The company does not pay dividends.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Customer Segments

You're mapping out the core groups PharmaCyte Biotech, Inc. (PMCB) needs to serve to make its Cell-in-a-Box® technology a commercial success. This isn't just about the end-user patient; it's about the entire ecosystem that enables the therapy to reach them, starting with the capital that funds the journey.

Biotech Investors and Shareholders seeking capital appreciation

This segment is crucial right now as PharmaCyte Biotech, Inc. (PMCB) is pre-revenue, with reported revenue of $0 million for the fiscal year ended April 30, 2025. Their interest is tied directly to the company's financial health and future potential. As of the latest reports, the company recently closed a $7.0 million financing in August 2025. The market capitalization as of September 15, 2025, was $7M, with the stock trading at $1.03. Ownership structure shows that Institutional Ownership stands at 8.57%, while Insider Ownership is 10.64%. The share count provides context for potential dilution and per-share value; as of July 31, 2025, there were 21,672,095 shares issued, with approximately 6.8 million common shares outstanding as of August 20, 2025. The company reported a net loss of -$8.36M last economic quarter, though net income for the fiscal year ending April 30, 2025, was $30.66 million, largely due to investment gains.

Oncologists and Hepatologists treating LAPC (future)

These are the specialists who will prescribe and manage the CypCaps™ therapy for locally advanced, inoperable pancreatic cancer (LAPC). The target market size for this indication is defined by the incidence of pancreatic cancer. For 2025 in the U.S., an estimated 67,440 new cases are projected. PharmaCyte Biotech, Inc. (PMCB)'s therapy targets the localized stage, which accounted for 15% of cases diagnosed between 2015 and 2021. The sheer number of specialists required to treat this patient base is significant, though a specific count for Hepatologists is not available. We can look at the broader oncology workforce as a proxy for the treating specialists.

Specialist Group	Relevant Count/Statistic	Date/Period of Data	Source Context
Total Actively Practicing Oncologists (U.S.)	25,419	2025	Active practice in the United States
Oncologists Billing Medicare (U.S.)	14,547	2024	Reported number
Hematology/oncology Physicians Tracked	11,937	October 2025	Most common tracked specialty
Medical Oncology Physicians Tracked	4,778	October 2025	Tracked specialty
Projected U.S. Oncologist Shortage	2,250	By 2025	Earlier projection

Patients with locally advanced, inoperable pancreatic cancer (future)

This is the initial, high-unmet-need patient population for the CypCaps™ product candidate. The overall pancreatic cancer incidence in the U.S. for 2025 is estimated at 67,440 new cases. The five-year relative survival rate for localized disease is 43.6%, compared to 3.2% for distant metastatic disease. The company's technology involves implanting encapsulated cells near the tumor site to activate a chemotherapy drug like ifosfamide.

Patients with insulin-dependent Type 1 and Type 2 diabetes (future)

This represents a significant, long-term expansion market for PharmaCyte Biotech, Inc. (PMCB)'s platform technology. The market for diabetes treatments is substantial, with the global Type 2 Diabetes Market size valued at $40.09 billion in 2025, and the U.S. segment at $10.82 billion. For Type 1 Diabetes, the global market was estimated at $16.97 Bn in 2025. The patient base in North America alone is large, with over 29 million people affected by diabetes, projected to rise to 32 million by 2025. Globally, the total number of people living with diabetes was 588.71 million in 2024.

• Global Type 2 Diabetes Market Size (2025): $40.09 billion
• U.S. Type 2 Diabetes Market Size (2025): $10.82 billion
• Global Type 1 Diabetes Market Size (2025 Estimate): $16.97 Bn
• North America Diabetes Prevalence (2025 Projection): 32 million people
• Global Diabetes Prevalence (2024): 588.71 million people

The Diabetes Stem Cell Therapy Market itself was valued at $5.4 Bn in 2024.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Cost Structure

You're looking at the core outflows for PharmaCyte Biotech, Inc. as of late 2025. For a company in clinical development, the cost structure is almost entirely non-revenue generating, focused on compliance, science, and keeping the lights on. It's a lean operation, but the costs associated with regulatory hurdles are significant.

The most immediate, non-recurring cost pressure comes from resolving the FDA clinical hold on the Investigational New Drug Application for pancreatic cancer. PharmaCyte Biotech, Inc. has engaged in specific service agreements to address the FDA's requests. The estimated total cost for these efforts is $212,000, with a portion of that, $157,000, specifically related to services from SG Austria and its subsidiaries to generate the necessary data submissions. This is a direct, targeted cost to unlock future revenue potential.

Research and Development (R&D) expenses, along with General and Administrative (G&A) expenses, form the bulk of the recurring operational spend. Looking at the quarter ended January 31, 2025, the total operating expenses were $960,252. For the nine-month period ending January 31, 2025, these operating expenses totaled $3,335,998. To be fair, these figures reflect a conscious reduction in costs from the prior year, specifically citing decreases in R&D costs, director fees, and general administrative costs.

Here's a quick look at the scale of those operating costs relative to the top-line result for that nine-month period:

Cost Category	Amount (Nine Months Ended Jan 31, 2025)
Total Operating Expenses	$3,335,998
Estimated FDA Hold Related Costs (Partial)	$212,000
Net Loss (Recent Quarter)	Approximately -$8.36 million

Personnel costs are kept to an absolute minimum, which is a key factor in managing the burn rate. As of April 30, 2025, PharmaCyte Biotech, Inc. maintained a very small core team, reporting only 2 employees. This minimal headcount directly contributes to lower compensation expenses, though compensation was still a line item that saw reductions in the nine months ended January 31, 2025.

The ultimate measure of the cost structure's impact on the bottom line is the net loss. For a recent economic quarter, the company reported a significant net loss of approximately -$8.36 million. This loss figure, while substantial, is viewed against a backdrop of strong liquidity following strategic asset monetization, suggesting management is funding the current cost base from reserves rather than immediate operations.

The cost structure is characterized by:

• Regulatory compliance spending directly tied to FDA resolution.
• Curtailment of R&D spending to conserve capital.
• Minimal G&A overhead due to a lean structure.
• Personnel costs anchored by a team of 2 employees.

Finance: draft 13-week cash view by Friday.

PharmaCyte Biotech, Inc. (PMCB) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of PharmaCyte Biotech, Inc.'s business model as of late 2025. For a company focused on clinical development, the revenue streams are currently dominated by non-operational activities, namely strategic capital deployment and financing events, rather than product sales.

Investment Gains from Strategic Capital Deployment

PharmaCyte Biotech, Inc. executed a significant move in late 2025 by successfully monetizing its stake in Femasys Inc. (NASDAQ: FEMY). This action validated the Company's strategic approach to capital allocation. Following this monetization, PharmaCyte's cash and marketable securities are expected to increase to approximately $20 million, which is up from $13.3 million as of July 31, 2025. This transaction is part of a broader strategy to strengthen the balance sheet.

To give you the full picture of the liquidity position around this event, here's a look at the key figures:

Metric	Date/Period End	Amount	Context
Cash and Securities	April 30, 2025	Approximately $15.5 million in cash and over $30 million in securities
Cash and Securities	July 31, 2025	$13.3 million
Capital Raise Proceeds	August 2025	$7 million
Cash and Securities (Expected Post-Monetization)	November 2025	Approximately $20 million
Total Cash and Marketable Securities (Post-Monetization)	November 2025	Roughly $20 million in cash plus approximately $25 million in marketable securities

The company is committed to deploying shareholder capital intelligently, balancing near-term returns with sustained value creation opportunities.

Recent Capital Raise

PharmaCyte Biotech, Inc. closed a financing round in August 2025, securing $7 million. This was achieved through a private placement involving the sale of Series C convertible preferred stock. The successful completion of this financing strengthened the balance sheet, providing financial flexibility to support ongoing business initiatives.

Key details of the August 2025 raise include:

• The financing involved the sale of 7,000 shares of Series C preferred stock.
• Each preferred share had a stated value of $1,000.
• The preferred stock is convertible into an aggregate of 7,000,000 shares of common stock.
• The conversion price is $1.00 per share of common stock.
• Unregistered common stock purchase warrants were issued to purchase up to 7,000,000 shares of common stock.
• Warrants are exercisable immediately at an exercise price of $1.00 per share for a term of five years.
• As of the release date, PharmaCyte had approximately 6.8 million shares of common stock outstanding.

Future Potential Licensing or Collaboration Revenue

As of late 2025, PharmaCyte Biotech, Inc. reports its future potential licensing or collaboration revenue as $0.

Future Potential Product Sales of CypCaps™

The Company's lead product candidate, CypCaps™, which uses the Cell-in-a-Box® technology for cellular therapies, currently generates no direct product sales revenue. As of late 2025, future potential product sales of CypCaps™ are reported as $0.

It's important to note that PharmaCyte Biotech's total operating revenue for the fiscal year 2025 ending April 30, 2025, was reported as $0.0. For the three months ended January 31, 2025, the total operating revenue was reported as -960,252 yuan, which was an improvement from the prior year's equivalent loss.